Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CDKN2A loss |
| Therapy | Palbociclib |
| Indication/Tumor Type | ovarian cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CDKN2A loss | ovarian cancer | sensitive | Palbociclib | Phase II | Actionable | In a Phase II trial (TAPUR), treatment with Ibrance (palbociclib) resulted in a disease control rate of 38% (10/27, 3 partial responses, 7 stable disease greater than 16 weeks), objective response rate of 11% (3/27), median progression-free survival of 8 weeks, and median overall survival of 33 weeks in patients with ovarian cancer harboring a CDKN2A alteration including loss (n=21), mutation (n=5), or both (n=2) (PMID: 42456088; NCT02693535). | 42456088 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42456088) | Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. | Full reference... |